Business
With Biogen’s multiple sclerosis portfolio facing more generic pressure than ever, the company is eyeing a busy late-stage pipeline and hunting for deals to build its return to growth.
FEATURED STORIES
Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call Tuesday, looking for any nugget of additional context.
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
After suffering in the wake of expired tax incentives for pharmas, the island is trying to take advantage of geopolitics to grow its drug manufacturing sector.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Pharma and biotech companies strengthen their leadership teams and boards with this week’s hires.
The analysis found 13 key problems, but one of the most relevant is that the stated purpose of the research—which is also under attack—did not occur.
Phoenix Solutions AS, a clinical-stage biotech company, announced the appointment of Dr. Jean-Michel Cosséry to its Board of Directors.
InDevR, Inc., a life science tools company focused on developing and commercializing novel analytical technologies for biologic process development and monitoring, announced that Ms. Terry Salyer has joined the company as Chief Commercial Officer.
Researchers from around the world are coming to present scientific research and clinical trial data for the disease.
Although there have been numerous variations on CRISPR that improve its effectiveness and apparent safety, there are still concerns about off-target edits and immune reactions to the Cas9 enzyme used to cut DNA.
Richard Sackler, the former president of Purdue Pharma, wanted prescribers to know that when it comes to treating pain, OxyContin was the way to go. And, in order to boost those sales, that meant the company had to downplay any concerns regarding the risk of addiction.
GeoVax Labs, Inc., a biotechnology company specializing in developing human vaccines, announced that its Chief Scientific Officer, Farshad Guirakhoo, PhD, will be a featured speaker at the World Vaccine & Immunotherapy conference, being held December 2-5, 2019 in San Francisco, California.
GeoVax Labs, Inc., a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, noted its observance of World AIDS Day 2019.
Experienced financial leader joins Xenikos as they enter the final stage of clinical development of T-Guard®